NCT04949529

Brief Summary

This longitudinal cohort study investigates cognitively normal participants with and without preclinical Alzheimer disease (AD) in order to examine: (1) the relationship between falls and functional mobility in preclinical stages of AD; and (2) a hypothesized model of central and peripheral mechanism(s) underlying falls and functional mobility in preclinical stages of AD.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
355

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2019

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 7, 2019

Completed
2.1 years until next milestone

First Submitted

Initial submission to the registry

April 9, 2021

Completed
3 months until next milestone

First Posted

Study publicly available on registry

July 2, 2021

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2025

Completed
Last Updated

August 26, 2025

Status Verified

August 1, 2025

Enrollment Period

6.2 years

First QC Date

April 9, 2021

Last Update Submit

August 25, 2025

Conditions

Keywords

Preclinical Alzheimer DiseaseFallsFunctional MobilityOlder Adults

Outcome Measures

Primary Outcomes (4)

  • Number and Severity of Falls

    Prospective monthly fall reporting will be collected using an automated phone/email system. Severity of falls will be calculated using a previously published algorithm.

    Cumulative falls at 4 years post-enrollment

  • Change from baseline: Dynamic balance and mobility

    Dynamic balance and mobility will be assessed using the Performance Oriented Mobility Assessment (POMA), a task-oriented assessment.

    4 years post-enrollment

  • Change from baseline: Gait Speed

    Gait speed will be collected using the Timed Up and Go (TUG) test.

    4 years post-enrollment

  • Change from baseline: Dual-task gait

    Dual-task gait will be collected using the Timed Up and Go Cognitive (TUGcog) and Timed Up and Go Manual (TUGman)

    4 years post-enrollment

Secondary Outcomes (11)

  • Fall Risk Composite Score

    4 years post-enrollment

  • Change from baseline: Standing balance and vestibular function

    4 years post-enrollment

  • Change from baseline: Lower extremity strength

    4 years post-enrollment

  • Change from baseline: Grip strength

    4 years post-enrollment

  • Change from baseline: Vision

    4 years post-enrollment

  • +6 more secondary outcomes

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersYes
Age GroupsOlder Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

A cohort of cognitively normal community-dwelling older adults who are currently undergoing comprehensive clinical, neuropsychological, and biomarker evaluations at the Knight Alzheimer's Disease Research Center (Knight ADRC) at Washington University in St. Louis.

You may qualify if:

  • years of age or older
  • cognitively normal (Clinical Dementia Rating \[CDR\] score of 0)
  • A pilot sub-study collecting stool will also enroll a few individuals with CDR\>0 for comparison.
  • have biomarkers (CSF), and/or neuroimaging (positron emission tomography \[PET\] and/or magnetic resonance imaging \[MRI\]) within 2 years of enrolling in this study.

You may not qualify if:

  • History of Parkinson's disease.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Washington University School of Medicine

St Louis, Missouri, 63110, United States

Location

Related Publications (1)

  • Bollinger RM, Keleman A, Thompson R, Westerhaus E, Fagan AM, Benzinger TL, Schindler SE, Xiong C, Balota D, Morris JC, Ances BM, Stark SL. Falls: a marker of preclinical Alzheimer disease: a cohort study protocol. BMJ Open. 2021 Sep 15;11(9):e050820. doi: 10.1136/bmjopen-2021-050820.

Biospecimen

Retention: SAMPLES WITH DNA

1. Whole blood sample 2. Cerebral spinal fluid (CSF) 3. Stool

MeSH Terms

Conditions

Alzheimer Disease

Condition Hierarchy (Ancestors)

DementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental Disorders

Study Officials

  • Susan L Stark, PhD

    Washington University School of Medicine

    PRINCIPAL INVESTIGATOR
  • Beau Ances, MD, PhD, MSc

    Washington University School of Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Occupational Therapy, Neurology, and Social Work

Study Record Dates

First Submitted

April 9, 2021

First Posted

July 2, 2021

Study Start

March 7, 2019

Primary Completion

April 30, 2025

Study Completion

April 30, 2025

Last Updated

August 26, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share

Locations